REPL (Replimune Group, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by REPL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-24 | Philip Astley-Sparke | Director | G | — | — |
| 2026-08-19 | Emily Luisa Hill | Chief Financial Officer | Sell | — | — |
| 2026-08-12 | Andrew Schwendenman | Chief Accounting Officer | Sell | — | — |
| 2026-08-12 | Emily Luisa Hill | Chief Financial Officer | Sell | — | — |
| 2026-08-12 | Konstantinos Xynos | Chief Medical Officer | Sell | — | — |
| 2026-08-12 | Sushil Patel | Chief Executive Officer | Sell | — | — |
| 2026-08-11 | JULIAN BAKER | Director | Buy | — | — |
| 2026-06-03 | Christopher Sarchi | Chief Commercial Officer | Sell | — | — |
| 2026-05-20 | Andrew Schwendenman | Chief Accounting Officer | Sell | — | — |
| 2026-05-20 | Sushil Patel | Chief Executive Officer | Sell | — | — |
| 2026-05-20 | Emily Luisa Hill | Chief Financial Officer | Sell | — | — |
| 2026-05-20 | Christopher Sarchi | Chief Commercial Officer | Sell | — | — |
| 2026-05-20 | Konstantinos Xynos | Chief Medical Officer | Sell | — | — |
| 2026-05-20 | Philip Astley-Sparke | Director | Sell | — | — |
| 2026-04-07 | Christopher Sarchi | Chief Commercial Officer | A | — | — |
| 2026-04-07 | Kapil Dhingra | Director | A | — | — |
| 2026-04-07 | Veleka Peeples-Dyer | Director | A | — | — |
| 2026-04-07 | Dieter Weinand | Director | A | — | — |
| 2026-04-07 | Paolo Pucci | Director | A | — | — |
| 2026-04-07 | Philip Astley-Sparke | Director | A | — | — |
| 2026-04-07 | Andrew Schwendenman | Chief Accounting Officer | A | — | — |
| 2026-04-07 | Christy J. Oliger | Director | A | — | — |
| 2026-04-07 | Konstantinos Xynos | Chief Medical Officer | A | — | — |
| 2026-04-07 | Madhavan Balachandran | Director | A | — | — |
| 2026-04-07 | 667, L.P. | Director | A | — | — |
| 2026-04-07 | Emily Luisa Hill | Chief Financial Officer | A | — | — |
| 2026-04-07 | Sushil Patel | Chief Executive Officer | A | — | — |
| 2026-04-07 | JOSEPH P SLATTERY | Director | A | — | — |
| 2026-04-06 | Christopher Sarchi | Chief Commercial Officer | Sell | — | — |
| 2026-02-20 | Philip Astley-Sparke | Director | G | — | — |
| 2025-12-19 | Andrew Schwendenman | Chief Accounting Officer | A | — | — |
| 2025-12-19 | Christopher Sarchi | Chief Commercial Officer | A | — | — |
| 2025-12-19 | Sushil Patel | Chief Executive Officer | A | — | — |
| 2025-12-19 | Emily Luisa Hill | Chief Financial Officer | A | — | — |
| 2025-12-19 | Konstantinos Xynos | Chief Medical Officer | A | — | — |
| 2025-12-11 | Kapil Dhingra | Director | MIXED | — | — |
| 2025-12-04 | Sushil Patel | Chief Executive Officer | Sell | — | — |
| 2025-11-19 | Christopher Sarchi | Chief Commercial Officer | Sell | — | — |
| 2025-11-19 | Konstantinos Xynos | Chief Medical Officer | Sell | — | — |
| 2025-08-19 | Emily Luisa Hill | Chief Financial Officer | Sell | — | — |
| 2025-05-22 | Konstantinos Xynos | Chief Medical Officer | Sell | — | — |
| 2025-05-22 | Philip Astley-Sparke | Director | Sell | — | — |
| 2025-05-22 | Emily Luisa Hill | Chief Financial Officer | Sell | — | — |
| 2025-05-22 | Sushil Patel | Chief Executive Officer | Sell | — | — |
| 2025-05-22 | Christopher Sarchi | Chief Commercial Officer | Sell | — | — |
| 2025-05-22 | Andrew Schwendenman | Chief Accounting Officer | Sell | — | — |
| 2025-04-03 | JOSEPH P SLATTERY | Director | A | — | — |
| 2025-04-03 | Emily Luisa Hill | Chief Financial Officer | A | — | — |
| 2025-04-03 | Madhavan Balachandran | Director | A | — | — |
| 2025-04-03 | Konstantinos Xynos | Chief Medical Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 9,475,522 | — |
| — | Director | 4,853,705 | — |
| — | Director | 4,811,398 | — |
| — | Director | 4,811,245 | — |
| — | Director | 4,588,116 | — |
| — | 10%+ Owner | 4,453,386 | — |
| — | 10%+ Owner | 2,486,296 | — |
| — | 10%+ Owner | 2,338,968 | — |
| — | President & Chief R&D Officer | 1,821,872 | — |
| — | Director | 1,362,414 | — |
| — | 10%+ Owner | 994,688 | — |
| — | Director | 946,000 | — |
| — | 10%+ Owner | 779,655 | — |
| — | Chief Operating Officer | 777,345 | — |
| — | Chief Executive Officer | 708,151 | — |
| — | Chief Business Officer | 268,794 | — |
| — | Chief Medical Officer | 224,215 | — |
| — | Chief Financial Officer | 215,852 | — |
| — | Chief Commercial Officer | 180,962 | — |
| — | Chief Dev. Op. Officer | 136,110 | — |
| — | Chief Financial Officer | 128,748 | — |
| — | Chief Accounting Officer | 99,425 | — |
| — | Chief Medical Officer | 58,067 | — |
| — | Chief Medical Officer | 21,500 | — |
| — | Director | 11,867 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the REPL quote page; the site-wide leaderboard is on the insider transactions hub.